IntelGenx Technologies Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Dwight Gorham

İcra Kurulu Başkanı

US$819.6k

Toplam tazminat

CEO maaş yüzdesi	20.2%
CEO görev süresi	1.3yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2.5yrs
Yönetim Kurulu ortalama görev süresi	8.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Dwight Gorham'un ücretlendirmesi IntelGenx Technologies'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2024	n/a	n/a	-US$11m
Dec 31 2023	US$820k	US$165k	-US$10m

Tazminat ve Piyasa: Dwight 'ın toplam tazminatı ($USD 819.56K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 650.80K ).

Tazminat ve Kazançlar: Dwight şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Dwight Gorham (66 yo)

1.3yrs

Görev süresi

US$819,564

Tazminat

Mr. Dwight Gorham serves as Chief Executive Officer of IntelGenx Technologies Corp. since April 13, 2023 and also serves as its Director since May 2024 and also Joined the company on April 13, 2023. He ser...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Dwight Gorham	CEO & Director	1.3yrs	US$819.56k	Veri yok
André Godin	President & CFO	9yrs	US$422.32k	0.44% $ 129.2k
Tommy Kenny	Senior VP & General Counsel	3.6yrs	US$176.92k	0.13% $ 37.0k
Nadine Paiement	Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp	no data	US$163.33k	0.093% $ 27.1k
Karen Kalayajian	Vice President of Finance & Administration	1.3yrs	Veri yok	0.16% $ 47.0k
Stephen Kilmer	Investor Relations Officer	no data	Veri yok	Veri yok
Ingrid Zerbe	Corporate Secretary	18.3yrs	Veri yok	0.053% $ 15.6k
Zenoz Pourhassan	VP of Quality Operations of Subsidiary	less than a year	Veri yok	Veri yok

2.5yrs

Ortalama Görev Süresi

53.5yo

Ortalama Yaş

Deneyimli Yönetim: IGXT 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Dwight Gorham	CEO & Director	less than a year	US$819.56k	Veri yok
Nadine Paiement	Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp	8.5yrs	US$163.33k	0.093% $ 27.1k
Mark Nawacki	Independent Vice Chairman	8yrs	US$83.59k	0% $ 0
Horst Zerbe	Chairman & Chairman of Scientific Advisory Board	18.3yrs	US$216.39k	0.0026% $ 758.4
Serge Gauthier	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Bernd Melchers	Independent Director	15.3yrs	US$83.59k	0.069% $ 20.0k
Barry Greenberg	Member of Scientific Advisory Board	8.5yrs	Veri yok	Veri yok
Ludwig Aigner	Member of Scientific Advisory Board	8.5yrs	Veri yok	Veri yok
Monika Trzcinska	Independent Director	2.3yrs	US$75.57k	Veri yok

8.5yrs

Ortalama Görev Süresi

61.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IGXT 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.5 yıldır).

IntelGenx Technologies Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

IntelGenx Technologies Corp. Announces Resignation of Dwight Gorham as Chief Executive Officer

IntelGenx Technologies Corp. Announces Board Resignations

IntelGenx Technologies Corp., Annual General Meeting, May 07, 2024

IntelGenx Technologies Corp. Announces Changes to its Board of Directors

IntelGenx Technologies Corp. Announces the Resignation of J. Bernard (Bernie) Boudreau from the Board of Directors

IntelGenx Technologies Corp. Elects Monika Trzcinska As Director

Recent updates

IntelGenx Technologies Corp. Announces Resignation of Dwight Gorham as Chief Executive Officer

IntelGenx Technologies Corp. announced delayed 10-Q filing

ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp. (OTCPK:IGXT).

IntelGenx Technologies Corp. Announces Board Resignations

Intelgenx Announces First Parkinson’S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ‘Montpark’ Clinical Trial

IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDA

IntelGenx Technologies Corp., Annual General Meeting, May 07, 2024

IntelGenx Technologies Corp. to Report Q4, 2023 Results on Mar 21, 2024

IntelGenx Technologies Corp. Announces Positive Results from Proof-Of-Concept Study to Assess the Palatability, Owner-Perceived Acceptability, and Ease of Repeated Administration of Intelgenx’s VetaFilm® Platform in Healthy Dogs and Cats

IntelGenx Technologies Corp. Announces Changes to its Board of Directors

IntelGenx Corp. Receives Approval to Conduct 'Montpark' Montelukast Versafilm Phase 2 Clinical Trial in Patients with Parkinson's Disease

IntelGenx Technologies Corp. to Report Q3, 2023 Results on Nov 09, 2023

Gensco® Pharma and Intelgenx Announces Rizafilm Commercialization Update in the United States

IntelGenx Corp. Provides Regulatory Update for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film

IntelGenx Technologies Corp. announced that it expects to receive CAD 9.43492 million in funding from ATAI Life Sciences AG

IntelGenx Technologies Corp. announced that it expects to receive CAD 8.42041 million in funding from ATAI Life Sciences AG

Intelgenx Technologies Corp. Completes Enrollment for `Buena' Montelukast Versafilm® Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease

IntelGenx Technologies Corp. to Report Q2, 2023 Results on Aug 14, 2023

Intelgenx Corp. Completes Enrollment for 'Buena' Montelukast Versafilm®? Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease

Intelgenx Corp. Provides Update on Research Collaboration Evaluating Montelukast Versafilm for the Treatment of Parkinson's Disease

IntelGenx Technologies Corp. Announces the Resignation of J. Bernard (Bernie) Boudreau from the Board of Directors

IntelGenx Technologies Corp. to Report Q1, 2023 Results on May 11, 2023

IntelGenx Corp. Receives FDA Pdufa Date for Rizafilm®

IntelGenx Technologies Corp. to Report Q3, 2022 Results on Nov 10, 2022

IntelGenx Files Provisional U.S. Patent Application for Advanced Oral Film Formulation Improving Cannabinoid Onset of Action

IntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film

IntelGenx Corp. Submits Response to CRL from FDA for RIZAPORT VersaFilm

IntelGenx Announces Enrollment Reaches Halfway Mark in ‘BUENA’ Montelukast VersaFilm Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

IntelGenx Technologies Corp. to Report Q2, 2022 Results on Aug 11, 2022

IntelGenx Technologies Corp. Elects Monika Trzcinska As Director

IntelGenx Technologies Corp. to Report Q1, 2022 Results on May 12, 2022

First Patient Dosed in IntelGenx Technologies Corp. Resumed ‘Buena’ Montelukast Versafilm Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

IntelGenx Technologies Corp. announced that it has received $2.1 million in funding

IntelGenx Technologies Corp. to Report Q4, 2020 Results on Mar 25, 2021

IntelGenx Technologies Corp., Annual General Meeting, May 11, 2021

IntelGenx Receives USPTO Notice of Allowance for its Novel DisinteQTM-Based Disintegrating THC Oral Film

IntelGenx Files Provisional U.S. Patent Application for Novel Vetafilmtm High Loading Oral Film Platform

Intelgenx Receives First Purchase Order for Cbd Filmstrips from Heritage Cannabis

IntelGenx Corp. Announces Publication of a Study Evaluating Montelukast’s Effect on Neurological Aging

IntelGenx Technologies Corp. to Report Q3, 2020 Results on Nov 12, 2020

Heritage Cannabis Holdings Corp. Signs Letter of Intent with Intelgenx Technologies Corp. for Long-Term Cannabis Filmstrip Supply Agreement

IntelGenx Technologies Corp. announced that it has received $1.2 million in funding

IntelGenx Technologies Corp. to Report Q2, 2020 Results on Aug 13, 2020

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş